Case analysis of significant efficacy of ivonib in patients with cholangiocarcinoma

Ivosidenib (Ivosidenib), as a targeted drug, has shown significant efficacy in the treatment of cholangiocarcinoma. In a phase III study, the median survival time of patients with cholangiocarcinoma treated with ivonib reached 2.7 months. Compared with 1.4 months in the placebo group, ivonib showed a clear efficacy advantage. This suggests that ivosidenib can prolong patient survival and provide a better prognosis.

The drug can reduce the carcinogenic metabolite2HG in the body and induce histone demethylation, thereby inhibiting the growth and development of tumors. This mechanism effectively controls the spread and metastasis of cancer cells, bringing new treatment hope to patients with cholangiocarcinoma.

A case report shows that a 72-year-old male cholangiocarcinoma patient achieved long-term disease control after receiving ivonib treatment with good safety profile and a significant improvement in his quality of life. After discovering the IDH1 mutation, this patient started receiving ivosidenib treatment and achieved remarkable results.

Traditional chemotherapy methods, such as gemcitabine combined with cisplatin, can prolong the survival of patients to a certain extent, but their efficacy is limited, and the median overall survival is only 11.7 months. As a new type of targeted drug, ivonib is expected to achieve more precise and effective treatment by targeting specific gene mutations.

In a multicenter, retrospective cohort study, patients with IDH1mutant cholangiocarcinoma who received immunotherapy had a median progression-free survival of only 2.73 span> months, whereas the median progression-free survival for patients treated with an IDH1 inhibitor was 5.4 months. This shows that for patients with cholangiocarcinoma with IDH1 mutations, IDH1 inhibitors such as ivonib may be more effective than immunotherapy.